GRI:NASDAQ, GRI Bio, Inc.

Why GRI stock fell on November 16

GRI Bio, Inc. fell 18.6% on Monday, November 16, 2026, on 115,586 shares. No headline about GRI came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

GRI stock overview

GRI Bio, Inc. (GRI:NASDAQ) closed at $1.40 on November 16, 2026, down 18.60% on the day. The stock trades 97.8% below its 52-week high of $64.12 and 2.9% above its 52-week low of $1.36. Over the past year, it lost 97.2%. GRI Bio, Inc. is part of the Health Care sector.

Key figures

Price
$1.40
Day change
-18.60%
Volume
115,586
Average volume
219,062
Market cap
3M+
52-week range
$1.36 – $64.12
50-day average
$1.77
200-day average
$2.04

Price action over the past year

In 252 trading sessions since November 14, 2025, GRI closed higher on 108 days (43%). Its best day was August 11, 2026 (+29.41%) and its worst was December 11, 2025 (-56.45%). The stock moved 10% or more in a single session 36 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

GRI news

About GRI Bio, Inc.

Vallon Pharmaceuticals Inc is a biopharmaceutical company, which focuses on the development and commercialization of proprietary biopharmaceutical products. The company develops prescription drugs for central nervous system disorders. Its product ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder, and narcolepsy.

Similar stocks

Find more stocks like GRI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.